Payment overview · 2025
General Payments
$384.00
21 reported records · 8 companies
Healthcare provider profile · identity verified
Michael Patrick Green, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PORT ALLEN, LA · NPI 1154400687
Verified facts
What the public records show
CMS Open Payments records show Michael Patrick Green, M.D. received $384.00 in general payments during 2025 across 21 reported records.
PFIZER INC. accounted for 39.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $150.12 | 39.1% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $84.95 | 22.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.95 | 16.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.84 | 5.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.79 | 5.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.01 | 5.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.61 | 4.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.73 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $384.00 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $105.75 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $105.75 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $84.95 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $84.27 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.37 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.37 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.44 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.51 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.51 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 160 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
204 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1023 | 293 |
| Amlodipine Besylate | Amlodipine Besylate | 1008 | 278 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 691 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 585 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 529 | 170 |
| Metoprolol Succinate | Metoprolol Succinate | 406 | 116 |
| Alprazolam | Alprazolam | 405 | 92 |
| Metformin Hcl | Metformin Hcl | 389 | 104 |
| Gabapentin | Gabapentin | 321 | 106 |
| Hydrochlorothiazide | Hydrochlorothiazide | 318 | 91 |
| Escitalopram Oxalate | Escitalopram Oxalate | 305 | 77 |
| Omeprazole | Omeprazole | 303 | 82 |
| Losartan Potassium | Losartan Potassium | 298 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 283 | 74 |
| Jardiance | Empagliflozin | 254 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 250 | 62 |
| Furosemide | Furosemide | 232 | 78 |
| Trazodone Hcl | Trazodone Hcl | 229 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 227 | 67 |
| Sertraline Hcl | Sertraline Hcl | 223 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 222 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 220 | 53 |
| Mounjaro | Tirzepatide | 217 | 45 |
| Lisinopril | Lisinopril | 214 | 65 |
| Eliquis | Apixaban | 204 | 41 |
| Montelukast Sodium | Montelukast Sodium | 199 | 55 |
| Benazepril Hcl | Benazepril Hcl | 190 | 53 |
| Carvedilol | Carvedilol | 186 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 181 | 33 |
| Simvastatin | Simvastatin | 180 | 52 |
| Tramadol Hcl | Tramadol Hcl | 179 | 61 |
| Celecoxib | Celecoxib | 175 | 71 |
| Mirtazapine | Mirtazapine | 175 | 44 |
| Potassium Chloride | Potassium Chloride | 174 | 50 |
| Metformin Hcl Er | Metformin Hcl | 163 | 51 |
| Ozempic | Semaglutide | 160 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 152 | 40 |
| Alendronate Sodium | Alendronate Sodium | 146 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 141 | 44 |
| Buspirone Hcl | Buspirone Hcl | 140 | 40 |
| Bupropion Xl | Bupropion Hcl | 138 | 39 |
| Risperidone | Risperidone | 132 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 124 | 40 |
| Glipizide Er | Glipizide | 123 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 32 |
| Ezetimibe | Ezetimibe | 105 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 102 | 31 |
| Allopurinol | Allopurinol | 99 | 30 |
| Lorazepam | Lorazepam | 98 | 19 |
| Meloxicam | Meloxicam | 97 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 92 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 28 |
| Clonazepam | Clonazepam | 90 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 21 |
| Januvia | Sitagliptin Phosphate | 80 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 70 |
| Glipizide | Glipizide | 79 | 15 |
| Baclofen | Baclofen | 76 | 27 |
| Donepezil Hcl | Donepezil Hcl | 75 | 17 |
| Glimepiride | Glimepiride | 74 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 72 | suppressed |
| Spironolactone | Spironolactone | 68 | 21 |
| Mupirocin | Mupirocin | 66 | 27 |
| Finasteride | Finasteride | 65 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 14 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 63 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 63 | suppressed |
| Methylprednisolone | Methylprednisolone | 60 | 54 |
| Diazepam | Diazepam | 59 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 44 |
| Synthroid | Levothyroxine Sodium | 58 | 14 |
| Irbesartan | Irbesartan | 57 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 16 |
| Linzess | Linaclotide | 57 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 12 |
| Fenofibrate | Fenofibrate | 56 | 15 |
| Latanoprost | Latanoprost | 55 | suppressed |
| Pregabalin | Pregabalin | 55 | 22 |
| Nifedipine Er | Nifedipine | 54 | 19 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 52 | suppressed |
| Ondansetron Odt | Ondansetron | 51 | 22 |
| Carbamazepine | Carbamazepine | 49 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 11 |
| Famotidine | Famotidine | 48 | 14 |
| Telmisartan | Telmisartan | 48 | 15 |
| Glyxambi | Empagliflozin/Linagliptin | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 16 |
| Ramipril | Ramipril | 46 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 44 | suppressed |
| Amoxicillin | Amoxicillin | 43 | 42 |
| Atenolol | Atenolol | 43 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 41 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 21 |
| Fluconazole | Fluconazole | 38 | 30 |
| Propranolol Hcl Er | Propranolol Hcl | 38 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 12 |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | 11 |
| Cefdinir | Cefdinir | 33 | 32 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | 11 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 12 |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Ramelteon | Ramelteon | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Nystatin | Nystatin | 25 | 13 |
| Olanzapine | Olanzapine | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Ciclopirox | Ciclopirox | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 23 | suppressed |
| Clotrimazole | Clotrimazole | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 23 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Alprazolam Er | Alprazolam | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Tacrolimus | Tacrolimus | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Tri-Lo-Mili | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Rifampin | Rifampin | 12 | 11 |
| Ursodiol | Ursodiol | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Prednisone | Prednisone | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $384.00 · 21 records | PFIZER INC. | ABRYSVO, AREXVY, CAPVAXIVE, COMIRNATY, FREESTYLE LIBRE 3, GARDASIL 9, NURTEC ODT, Ozempic, PREVNAR 20, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error